Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.


BACKGROUND Ivacaftor improves outcomes in cystic fibrosis (CF) patients with the G551D mutation; however, effects on respiratory microbiology are largely unknown. This study examines changes in CF respiratory pathogens with ivacaftor and correlates them with baseline characteristics and clinical response. METHODS The G551D Observational Study enrolled a… (More)
DOI: 10.1093/cid/ciu944

6 Figures and Tables


  • Presentations referencing similar topics